Renal Insufficiency

Nephrology·MeSH: Renal Insufficiency

Prevalence

0.1 / 100K

14 drugs in development·7 companies·8 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
incb054707	Incyte Corp. (INCY)
LY3537982	ELI LILLY & Co (LLY)

Phase 2(2)

Drug	Company
efmody	NEUROCRINE BIOSCIENCES INC (NBIX)
gemini	REVELATION BIOSCIENCES, INC. (REVB)

Phase 1(3)

Drug	Company
gemini-aki	REVELATION BIOSCIENCES, INC. (REVB)
gemini-ckd	REVELATION BIOSCIENCES, INC. (REVB)
ly3502970	ELI LILLY & Co (LLY)

Preclinical(2)

Drug	Company
et-800	Eton Pharmaceuticals, Inc. (ETON)
gemini-psi	REVELATION BIOSCIENCES, INC. (REVB)

BLA Filed(1)

Drug	Company
et-400	Eton Pharmaceuticals, Inc. (ETON)

Phase 1/Phase 2(1)

Drug	Company
intravenous gemini	REVELATION BIOSCIENCES, INC. (REVB)

Phase 4(3)

Drug	Company
balcinrenone/dapagliflozin	ASTRAZENECA PLC (AZN)
Dapagliflozin 10mg Tab	ASTRAZENECA PLC (AZN)
Dapagliflozin 10Mg Tab	Travere Therapeutics, Inc. (TVTX)

BioSniper tracks 14 drugs in development for Renal Insufficiency across 7 companies.

There are 8 clinical trials targeting Renal Insufficiency tracked by BioSniper.

The estimated prevalence of Renal Insufficiency is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.